Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07058987
Starting soon Not applicable

Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation

NCT07058987 · tracked via the Priya Life Science China tracker
Sponsor
Lanzhou University Second Hospital
Phase
Not applicable
Started
2025-07-15
Last updated
2025-07-14

Condition(s) studied

Atrial Fibrillation (AF)Heart Failure (HF)Cardiac Rehabilitation

Investigational drug(s) / intervention(s)

Cardiac Rehabilitation Combined With EECPRoutine Medical Care

Cardiac Rehabilitation Combined With EECP: This intervention consists of a comprehensive cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support, and lifestyle counseling, combined with enhanced external counterpulsation (EECP) therapy administered according to standard cardiovascular protocols. The combined intervention is designed to improve cardiac function, exercise tolerance, and quality of life in patients with atrial fibrillation.

Routine Medical Care: Participants in the control group will receive standard medical treatment for atrial fibrillation as prescribed by their attending physicians, without enhanced external counterpulsation or structured cardiac rehabilitation. This may include pharmacological therapy, routine clinical monitoring, and general lifestyle advice.

Study summary

This is a prospective randomized controlled trial designed to evaluate the effectiveness of enhanced external counterpulsation (EECP) combined with cardiac rehabilitation in patients with atrial fibrillation. The study aims to assess whether this combined intervention can improve cardiac function and exercise capacity compared to standard care alone. Eligible participants will be randomly assigned to receive either the EECP plus cardiac rehabilitation program or routine treatment. Primary outcomes include changes in left ventricular ejection fraction (LVEF) and six-minute walking distance (6MWD). The study will be conducted at Lanzhou University Second Hospital.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 40 and 80 years * Diagnosed with persistent or paroxysmal atrial fibrillation, confirmed by ECG or Holter * Stable medical condition and able to participate in cardiac rehabilitation and EECP therapy * Provided written informed consent Exclusion Criteria: * Recent acute myocardial infarction, unstable angina, or decompensated heart failure within the past 4 weeks * Severe valvular heart disease or left ventricular ejection fraction \<30% * Severe peripheral vascular disease or deep vein thrombosis * Severe pulmonary disease or active infection * History of bleeding disorders or contraindications to EECP * Cognitive impairment or psychiatric condition affecting study participation * Participation in another clinical trial within the past 3 months

Primary outcome measure(s)

  • Change in Left Ventricular Ejection Fraction (LVEF) from Baseline to Week 12 — Baseline and 12 weeks after intervention
    LVEF will be assessed using transthoracic echocardiography to evaluate improvement in systolic cardiac function.

Trial sites (1)

FacilityCityRegionStatus
Lanzhou University Second Hospital Lanzhou Gansu

More Lanzhou University Second Hospital trials in China

Effect of Intrauterine Insemination on Subsequent Pregnancy Outcomes in Couples With Unexplained Pregnancy Loss: A Multicenter, Open-label, Randomized Controlled Trial Recruiting
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery Active, not recruiting
Clinical Validation of a Blood Loss Monitoring System Enrolling by invitation
Effect of Negative Pressure Suction on Fluid Absorption and Infection in Flexible Ureteroscopy Recruiting

Other trials for the same condition

Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation Starting soon
Electronic Blood Pressure Monitor for Atrial Fibrillation Detection Starting soon
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation Recruiting
Comparative Study on the Safety and Efficacy of Using AccuSafe Transseptal Guidewire Versus Traditional Transseptal Needle for Transseptal Puncture in non-or Free- Guidance Recruiting
The COMBINE-AF Trial Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07058987 on ClinicalTrials.gov ↗ ← All trials in China